Version July 2025
| Name | Form | Manufacturer | Authorization |
| Pandemic influenza H5N1 vaccine | Monovalent subunit (nonadjuvanted) | Sanofi | United States (2007) |
| Arepanrex | Monovalent recombinant H5N1 subunit vaccine adjuvanted with AS03 | GlaxoSmithKline | United States (2013) |
| Adjupanrix | Monovalent recombinant H5N1 subunit vaccine adjuvanted with AS03 | GlaxoSmithKline | European Union (2009) |
| Aflunov | Monovalent subunit H5N1 vaccine adjuvanted with MF59 | Novartis | European Union (2010) |
| Foclivia | Monovalent subunit H5N1 vaccine adjuvanted with MF59 | Seqirus | European Union (2011) |
| Audenz | Monovalent subunit H5N1 vaccine adjuvanted with MF59 | Seqirus | United States (2020) |
| Zoonotic influenza vaccine | Monovalent subunit H5N8 vaccine adjuvanted with M59 | Seqirus | European Union (2023) United States (2024) |
| Pandemic influenza vaccine H5N1 Baxter AG | Whole-virion vaccine | Baxter (previously Celvapan) | European Union (2009) |
| Pandemic influenza vaccine H5N1 AstraZeneca | Live attenuated, nasal vaccine | AstraZeneca | European Union (2016) |
